AU2023246384A1 — Method of treating medulloblastoma with an ezh2 inhibitor
Assigned to Epizyme Inc · Expires 2023-11-02 · 3y expired
What this patent protects
The disclosure provides a method of treating a medulloblastoma in a subject in need thereof comprising administering to the subject a therapeutically-effective amount of an enhancer of a zeste homolog 2 (EZH2) inhibitor. In a preferred embodiment of this method, the subject is …
USPTO Abstract
The disclosure provides a method of treating a medulloblastoma in a subject in need thereof comprising administering to the subject a therapeutically-effective amount of an enhancer of a zeste homolog 2 (EZH2) inhibitor. In a preferred embodiment of this method, the subject is pediatric and the EZH2 inhibitor is Tazemetostat. See Fig. 16A. WO 2017/062495 PCT/US2016/055554 26/41 FIG. 16A -- Vehicle 2800 - -- 125 mg/kg 2400 - Ar- 250 mg/kg ---T---500 mg/kg E E 2000 ----------------------- ------------------------ 1600 E Cpd A > 1200 0 E 800 400 ~~A~~~-A,-A - .. A--AA 0 10 20 30 40 50 60 Days FIG. 16B 2.5 00 All dosed groups vs. vehicle 0 2.0- e M 1.5 M 1.0 0.5 -EN V A U *E 4AA.. 0.0 125 1i Vehicle 125 250 500 20 pM mg/kg BID x 21 Compound A
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.